Allogeneic Anti-CD19 CAR T-cells ATA3219

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic human Epstein-Barr virus (EBV)-sensitized T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with a modified CD3zeta signaling domain 1xx, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 CAR T-cells ATA3219 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The use of allogeneic EBV T-cells minimizes the risks for graft-versus-host disease (GvHD). The modified CD3zeta signaling domain 1xx retains signaling capacity in 1 of 3 immune-receptor-tyrosine-based-activation-motif (ITAM) regions, which may help prevent counterproductive T-cell differentiation and exhaustion, and may enhance the anti-tumor activity of the CAR T-cells.

**Synonyms:** - ATA 3219 - ATA-3219 - ATA3219 - Allogeneic Anti-CD19 CAR T Cells ATA3219 - Allogeneic Anti-CD19 CAR-T Cells ATA3219